Hironori Harada

USPTO Granted Patents = 10 (Patent Applications = 2)

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 2)

Average Co-Inventor Count = 7.6

ph-index = 3

Forward Citations = 48(Granted Patents)

Location History:

Matsudo, JP (2000)
Tsukuba, JP (2004 - 2007)
Chuo-ku, JP (2009 - 2010)
Tokyo, JP (2010 - 2023)

Company Filing History:

Yamanouchi Pharmaceutical Company Ltd.

where one patent can have more than one assignee

Years Active: 2000-2023

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11578067 - Compound, and method for producing regulatory T cells (2023-02-14),

2. 8193378 - 2H-chromene compound and derivative thereof (2012-06-05),

3. 8163746 - Azolecarboxamide derivative (2012-04-24),

4. 7951825 - Hetero compound (2011-05-31),

5. 7855198 - Benzamide derivative or salt thereof (2010-12-21),

6. 7678820 - Hetero compound (2010-03-16),

7. 7585878 - Benzamide derivative or salt thereof (2009-09-08),

8. 7232904 - Crystal of arylethenesulfonamide derivative and preparation process thereof (2007-06-19),

9. 6774131 - Remedies for endothelin-induced diseases (2004-08-10),

10. 6083955 - Arylethenesulfonamide derivatives and drug composition containing the (2000-07-04),

Title: Hironori Harada: Innovator in Therapeutic Compounds

Introduction

Hironori Harada is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of therapeutic compounds, holding a total of 10 patents. His work focuses on innovative methods and compounds that have the potential to revolutionize treatments for various diseases.

Latest Patents

One of Harada's latest patents is titled "Compound, and method for producing regulatory T cells." This invention provides a novel compound that exhibits CDK8 and/or CDK19 inhibitory activity, along with a method for producing Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells, allowing for the induction of Foxp3T cells in vitro.

Another significant patent is for a "2H-chromene compound and derivative thereof." This invention presents a compound with excellent S1P agonist action, which is particularly useful as an active ingredient for agents aimed at preventing or treating diseases caused by undesirable lymphocyte infiltration or abnormal cell proliferation. The 2H-chromene compound and its derivatives can be effectively utilized in the prevention and treatment of such diseases.

Career Highlights

Throughout his career, Hironori Harada has worked with notable companies, including Astellas Pharma GmbH and Yamanouchi Pharmaceutical Company Ltd. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.

Collaborations

Harada has collaborated with esteemed colleagues such as Kazuyuki Hattori and Kazuya Fujita. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking inventions.

Conclusion

Hironori Harada's contributions to the field of therapeutic compounds are noteworthy, with a focus on innovative methods and compounds that hold promise for treating various diseases. His work continues to impact the medical field positively, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.